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Abstract 
This report describes the additional certification of the mass concentration of beta-2-microglobulin (B2M) in ERM-DA470k/IFCC, a human serum 
material. The material was released in 2008 and was certified for the mass concentration of 12 proteins in human serum. The material is now 
additionally certified for B2M in accordance with ISO Guide 34:2009. 
A full description of the processing steps used to produce the material can be found in the first report. 
The between unit-homogeneity was quantified and the stability during dispatch and storage were assessed in accordance with ISO Guide 35:2006. 
The within-unit homogeneity was estimated to determine the minimum sample intake. 
The material was characterised by an inter-laboratory comparison exercise performed by laboratories of demonstrated competence and with 
adherence to ISO/IEC 17025. 
Uncertainties of the certified values were calculated in accordance with the Guide to the Expression of Uncertainty in Measurement (GUM) and include 
uncertainties relating to possible lack of homogeneity, instability and to characterisation. 
The material is intended for the calibration or control, for the certified proteins only, of immunoassay-based in-vitro diagnostic devices or control 
products. Any other calibrator should be verified as commutable. The material was produced in a similar manner as ERM-DA470, the use of which has 
led to a significant reduction in the between-method and between-laboratory variation for the proteins certified (B2M was not certified in this 
material) [ , ]. It was verified during the value assignment procedure that there were no significant matrix effects, and that different methods 
produced consistent results. The Certified Reference Material (CRM) is available in the lyophilised form of a 1.0 mL portion of serum with additives (4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), sodium azide, benzamidine hydrochloride, sodium chloride and aprotinin). The CRM is 
available in threaded glass bottles with rubber stoppers and polypropylene screw caps maintained under nitrogen gas. The water mass fraction of the 
sample is (4.3 ± 0.6) mg/g. The lyophilised powder has to be reconstituted with (1.00 ± 0.01) g of distilled water and the minimum amount of 
reconstituted sample to be used for B2M measurement is 2 µL. 
The CRM including its B2M certified value was accepted as European Reference Material (ERM®) after peer evaluation by the partners of the European 
Reference Materials consortium..  
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Summary 
This report describes the additional certification of the mass concentration of  
beta-2-microglobulin (B2M) in ERM-DA470k/IFCC, a human serum material. The material 
was released in 2008 and was certified for the mass concentration of 12 proteins in human 
serum. The material is now additionally certified for B2M in accordance with ISO Guide 
34:2009 [1]. 
A full description of the processing steps used to produce the material can be found in the 
first report [2]. 
The between unit-homogeneity was quantified and the stability during dispatch and storage 
were assessed in accordance with ISO Guide 35:2006 [3]. The within-unit homogeneity was 
estimated to determine the minimum sample intake. 
The material was characterised by an inter-laboratory comparison exercise performed by 
laboratories of demonstrated competence and with adherence to ISO/IEC 17025 [4]. 
Uncertainties of the certified values were calculated in accordance with the Guide to the 
Expression of Uncertainty in Measurement (GUM) [5] and include uncertainties relating to 
possible lack of homogeneity, instability and to characterisation. 
The material is intended for the calibration or control, for the certified proteins only, of 
immunoassay-based in-vitro diagnostic devices or control products. Any other calibrator 
should be verified as commutable. The material was produced in a similar manner as ERM-
DA470 [6], the use of which has led to a significant reduction in the between-method and 
between-laboratory variation for the proteins certified (B2M was not certified in this material) 
[7,8]. It was verified during the value assignment procedure that there were no significant 
matrix effects, and that different methods produced consistent results. The Certified 
Reference Material (CRM) is available in the lyophilised form of a 1.0 mL portion of serum 
with additives (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), sodium azide, 
benzamidine hydrochloride, sodium chloride and aprotinin). The CRM is available in 
threaded glass bottles with rubber stoppers and polypropylene screw caps maintained under 
nitrogen gas. The water mass fraction of the sample is (4.3 ± 0.6) mg/g. The lyophilised 
powder has to be reconstituted with (1.00 ± 0.01) g of distilled water and the minimum 
amount of reconstituted sample to be used for B2M measurement is 2 µL. 
The CRM including its B2M certified value was accepted as European Reference Material 
(ERM®) after peer evaluation by the partners of the European Reference Materials 
consortium. 
The following value for B2M was assigned: 
Protein in the reconstituted 
material (see section 9.3) 
Mass concentration 
Certified value 2) 
[mg/L] 
Uncertainty 3) 
[mg/L] 
Beta-2-microglobulin 
(B2M) 1) 
2.17 0.07 
1) B2M as measured by immunonephelometry, immunoturbidimetry, fluorometric enzyme immunoassay and 
chemiluminescent immunoassay using a pure protein solution as calibrant. 
2) The value is the unweighted mean of 13 accepted mean values, independently obtained by 13 laboratories. The 
certified mass concentration is traceable to the SI, via calibration with a pure protein solution of B2M. 
3) Expanded uncertainty U with a coverage factor k = 2, corresponding to a level of confidence of approxiamtely 95 %, 
estimated in accordance with the Guide to the Expression of Uncertainty in Measurement (GUM), ISO, 1995. 
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Glossary 
ANOVA  Analysis of variance 
b Slope in the equation of linear regression y = a + bx 
B2M beta-2-microglobulin 
BSA Bovine serum albumin 
c Mass concentration c = m / V (mass / volume) 
CI confidence interval 
CLSI Clinical and Laboratory Standards Institute 
CRM Certified reference material 
EC European Commission 
 Concentration of the target material 
() Concentration of the target material in the dilution  
ERM® Trademark of European Reference Materials 
GUM Guide to the Expression of Uncertainty in Measurements [5] 
, Dilution factor for the material for dilution 	 

(	) Dilution factor for the target material for dilution 	 
HBV Hepatitis B virus 
HBs Hepatitis B surface antigen 
HCV Hepatitis C virus 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HG-AFS Hydride generation-atomic fluorescence spectrometry 
HIV Human immunodeficiency virus 
HTLV Human T-cell lymphotropic virus 
IFCC International Federation of Clinical Chemistry and Laboratory Medicine 
IRMM Institute for Reference Materials and Measurements of the JRC  
ISO International Organization for Standardization  
ISS International staging system 
IU International units 
IVD In Vitro Diagnostics 
JRC Joint Research Centre of the European Commission 
k Coverage factor 
m Mass 
MD Medical devices 
MRL Maximum residue limit 
MS Mass spectrometry 
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MSbetween Mean of squares between-unit from an ANOVA 
MSwithin  Mean of squares within-unit from an ANOVA 
n Number of replicates per unit 
nns Number of results from the normal stock 
nref Number of results from the reference stock 
N Number of samples (units) analysed 
n.a. Not applicable 
n.c. Not calculated 
p Number of accepted datasets 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffer saline 
rel Index denoting relative figures (uncertainties etc.) 
RM Reference material 
RSD Relative standard deviation 
RSE Relative standard error (=RSD/√n) 
r2 Coefficient of determination of the linear regression 
s Standard deviation 
sbb
 Between-unit standard deviation; an additional index "rel" is added when 
appropriate 
sbetween Standard deviation between groups as obtained from ANOVA; an 
additional index "rel" is added as appropriate 
SDS Sodium dodecyl sulphate 
SI International System of Units 
smeas Standard deviation of measurement data; an additional index "rel" is 
added as appropriate 
sns Standard deviation of results of normal stock samples 
sref Standard deviation of results of normal stock samples 
swithin Standard deviation within groups as obtained from ANOVA; an additional 
index "rel" is added as appropriate 
swb Within-unit standard deviation 
tsl Proposed shelf life 
TM target material 
TF Transfer factor 
TRIS Tris(hydroxymethyl)aminomethane 
u standard uncertainty  
U expanded uncertainty 
u*bb  Standard uncertainty related to a maximum between-unit inhomogeneity 
that could be hidden by method repeatability; an additional index "rel" is 
added as appropriate 
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ubb Standard uncertainty related to a possible between-unit inhomogeneity;  
an additional index "rel" is added as appropriate 
uc combined standard uncertainty; an additional index "rel" is added as 
appropriate 
ucal Standard uncertainty of the calibrant 
uchar  Standard uncertainty of the material characterisation; an additional index 
"rel" is added as appropriate 
uCRM Combined standard uncertainty of the certified value; an additional index 
"rel" is added as appropriate 
UCRM  Expanded uncertainty of the certified value; an additional index "rel" is 
added as appropriate 
u∆ Combined standard uncertainty of measurement result and certified 
value 
U∆ Combined expanded uncertainty of measurement result and certified 
value 
ults Standard uncertainty of the long-term stability; an additional index "rel" is 
added as appropriate 
umeas Standard measurement uncertainty 
Umeas Expanded measurement uncertainty 
usts Standard uncertainty of the short-term stability; an additional index "rel" 
is added as appropriate 
xi Result at time point i 
̅ Mean of all results for all time points in the stability study 
̅ Mean of all results of normal stock samples 
̅ Mean of all results of reference stock samples 
 Mean of all results in the homogeneity study 
∆meas Absolute difference between mean measured value and the certified 
value 
νs,meas Degrees of freedom for the determination of the standard deviation smeas 
MSwithinν
 
Degrees of freedom of MSwithin 
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1 Introduction  
1.1 Background 
Serum beta-2-microglobulin (B2M) is an important marker used in the investigation of 
patients with multiple myeloma and lymphoma. The international staging system (ISS) [9] 
uses concentrations of serum albumin and B2M to classify patients into prognostic groups. 
The important values for B2M are below 3.5 mg/L for the "good" prognostic category and 
above 5.5 mg/L for the poorer prognostic category. Recent work has highlighted the 
discrepancies between results obtained in different laboratories for B2M measurements 
leading to difficulties in implementing the staging system [10]. Therefore, the Institute for 
Reference Materials and Measurements (IRMM) was asked by the International Federation 
for Clinical Chemistry and Laboratory Medicine (IFCC) to develop a reference material to 
support the standardisation of B2M measurements. 
The EU Directive on In Vitro Diagnostic Medical Devices (IVD-MD) (Directive 98/79/EC) [11] 
requires traceability of the assigned values of calibrants and control materials to reference 
measurement procedures and/or reference materials of higher order. 
1.2 Design of the project 
The material was characterised through a value transfer procedure [12]. In this procedure, a 
pure protein solution spiked into an appropriate background is used to calibrate of the 
measurements of the candidate reference material. Six dilutions of the pure protein solution 
were measured in parallel with six dilutions of ERM-DA470k/IFCC. 
The techniques used to measure the protein concentrations were immunonephelometry and 
immunoturbidimetry, fluorometric enzyme immunoassay and chemiluminescent 
immunoassay. The measurements were performed with different instruments (Abbott 
Architect c8000, Beckman Coulter AU480, Hitachi 917, Hitachi 7180, Roche Cobas c501, 
Siemens BN ProSpec®, Tosoh AIA-2000 and SpherelightTM Wako) and reagents. In total 
thirteen laboratories participated in the value assignment. Most characterisation 
measurements were performed under an ISO 13485 quality system. 
2 Participants 
2.1 Project management and evaluation 
European Commission, Joint Research Centre, Institute for Reference Materials and 
Measurements (IRMM), Geel, BE  
(accredited to ISO Guide 34 for production of certified reference materials, BELAC No. 268-RM) 
2.2 Processing and homogeneity study 
European Commission, Joint Research Centre, Institute for Reference Materials and 
Measurements (IRMM), Geel, BE  
(accredited to ISO Guide 34 for production of certified reference materials, BELAC No. 268-RM) 
Siemens Healthcare Diagnostics Products GmbH , Marburg, DE 
2.3 Stability study 
European Commission, Joint Research Centre, Institute for Reference Materials and 
Measurements (IRMM), Geel, BE  
(accredited to ISO Guide 34 for production of certified reference materials, BELAC No. 268-RM) 
Olympus Life and Materials Science, Clare, IE 
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Siemens Healthcare Diagnostics Products GmbH , Marburg, DE 
2.4 Characterisation 
Abbott Diagnostics Division, Irving, Texas, US 
A&T Corporation, Kanagawa, JP 
Centro Interdipartimentale per la Riferibilità Metrologica in Medicina di Laboratorio (CIRME), 
Universita degli Studi di Milano, Milano, IT (measurements under the scope of ISO/IEC 17025 
accreditation ACCREDIA; 217 rev. 01) 
DAKO Denmark A/S, Glostrup, DK 
Denka Seiken Co., Ltd, Niigata, JP 
Eiken Chemical Co., Ltd, Tokyo, JP 
LSI Medience Corporation, Tokyo, JP 
Nittobo Medical Co., Ltd, Fukushima, JP 
Roche Diagnostics GmbH, Penzberg, DE  
Sanyo Chemical Industries, Ltd., Kyoto, JP 
St Georges Hospital, Protein Reference Unit, London, UK (measurements under the scope of 
Clinical Pathology Accreditation, United Kingdom Accreditation Services; CPA 1929) 
Tosoh Corporation, Tokyo, JP 
Wako Pure Chemical Industries, Ltd., Osaka, JP 
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3 Material processing and process control 
The processing of the material is described in the first report for ERM-DA470k/IFCC [2]. 
4 Homogeneity 
A key requirement for any certified reference material aliquoted into units is the equivalence 
between those units. It is important to establish whether the variation between units of the 
reference material is significant compared to the uncertainty of the certified value, although, it 
is not relevant if this variation between units is significant compared to the analytical 
variation. ISO Guide 34 requires RM producers to quantify the between unit variation. This 
aspect is covered by between-unit homogeneity studies. 
The within-unit inhomogeneity does not influence the uncertainty of the certified value when 
the minimum sample intake is respected, but determines the minimum size of an aliquot that 
is representative for the whole unit. Quantification of within-unit inhomogeneity is therefore 
necessary to determine the minimum sample intake. 
4.1 Between-unit homogeneity 
The between-unit homogeneity was evaluated to ensure that the certified value of the CRM 
was valid for all units of the material, within the stated uncertainty. 
For the between-unit homogeneity assessment, the number of units selected corresponds to 
approximately the cubic root of the total number of the units produced and therefore forty 
units were selected using a random stratified sampling scheme covering the whole batch for 
the between-unit homogeneity test. For this, the entire batch was divided into forty groups 
(containing a similar number of units) and one unit was selected at random from each group. 
Three independent samples were taken from each of these units, and analysed by 
immunonephelometry. The measurements were performed in a randomised manner to be 
able to separate a potential analytical drift from a trend in the filling sequence. 
Regression analyses were performed to evaluate potential trends in the analytical sequence 
as well as trends in the filling sequence. No trends in the filling sequence or the analytical 
sequence were visible. 
Quantification of between-unit inhomogeneity was undertaken by analysis of variance 
(ANOVA), which separates the between-unit variation (sbb) from the within-unit variation (swb). 
The latter is equivalent to the method repeatability if the individual samples are 
representative for the whole unit.  
Evaluation by ANOVA requires mean values per unit which follow at least a unimodal 
distribution and results for each unit that follow unimodal distributions with approximately the 
same standard deviations. The distribution of the mean values per unit was assessed using 
histograms and normal probability plots to determine if the data followed a unimodal 
distribution. Minor deviations from unimodality of the individual values do not significantly 
affect the estimate of between-unit standard deviations.  
It should be noted that relbbs ,  and relwbs ,  are estimates of the true standard deviations and 
therefore subject to random fluctuations. Therefore, the mean square between groups  
( betweenMS ) can be smaller than the mean squares within groups ( withinMS ), resulting in 
negative arguments under the square root used for the estimation of the between-unit 
variation, whereas the true variation cannot be lower than zero. In this case, * relbbu , , the 
maximum inhomogeneity that could be hidden by method repeatability, was calculated as 
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described by Linsinger et al. [13]. * relbbu ,  and is comparable to the limit of detection of an 
analytical method, yielding the maximum inhomogeneity that might be undetected by the 
given study setup.  
Method repeatability ( relwbs , ), between–unit standard deviation ( relbbs , ) and * relbbu ,  were 
calculated as in Equations 1, 2 and 3:  
y 
MS
s withinrelwb =,  Equation 1 
y
n
MSMS
s
withinbetween
relbb
−
=
,
 Equation 2 
y
νn
MS
u MSwithin
within
*
relbb
4
,
2
=  Equation 3 
where: 
withinMS  mean square within a unit from an ANOVA  
betweenMS  mean squares between-unit from an ANOVA 
y  mean of all results of the homogeneity study 
n mean number of replicates per unit 
MSwithinν  degrees of freedom of MSwithin  
The results of the measurements are shown in Annex A. The results of the evaluation of the 
between-unit variation are summarised in Table 1. 
Table 1: Results of the homogeneity study 
 
relwbs ,   
[%]
 
relbbs ,  
[%]
 
*
relbbu ,  
[%] 
relbbu ,  
[%] 
B2M 2.90 n.c.1) 0.67 0.67 
 
1)
 n.c.: cannot be calculated as MSbetween < MSwithin 
The homogeneity study showed no outlying unit means or trends in the filling sequence. 
Therefore the between-unit standard deviation can be used as estimate of ubb. As u*bb sets 
the limits of the study to detect inhomogeneity, the larger value of sbb and u*bb is used as 
uncertainty contribution to account for potential heterogeneity. 
4.2 Within-unit homogeneity and minimum sample intake 
The material is a solution and is not expected to have any heterogeneity. This assumption 
was confirmed by the homogeneity/stability/characterisation study, where sample intakes as 
low as 2 µL were found to give acceptable repeatability, demonstrating that there is no 
heterogeneity or contamination at a sample intake of 2 µL. 
Therefore the minimum sample intake is 2 µL.  
 11 
5 Stability 
Time and temperature were regarded as the most relevant influences on the stability of the 
material.  
Stability testing is necessary to establish the conditions for storage (long-term stability) as 
well as the conditions for dispatch of the material to the customers (short-term stability). 
During transport, especially in summer time, temperatures up to 60 °C can be reached and 
stability under these conditions must be demonstrated if the materials are to be transported 
at ambient temperatures. 
The stability studies were performed using an isochronous design [14]. In this approach, 
units were stored for a specified length of time at different temperatures whereupon the units 
were then moved to conditions where further degradation was assumed to be negligible 
(reference conditions). At the end of the isochronous storage, the samples were analysed 
simultaneously under repeatability conditions. Analysis of the material (after various 
exposure times and temperatures) under repeatability conditions greatly improves the 
sensitivity of the stability tests.  
5.1 Short-term stability study 
For the short-term stability study, units of ERM-DA470k/IFCC were stored at -70 °C, -20 °C, 
4 °C and 60 °C for 0, 1, 2 and 4 weeks. The reference temperature was set to -150 °C 
(above liquid nitrogen). Two units per storage time were selected using a random stratified 
sampling scheme. Three samples, taken from each unit, were analysed by 
immunonephelometry, under repeatability conditions, in a randomised sequence, to be able 
to separate a potential analytical drift from a trend over storage time. 
The data were evaluated for each temperature individually. No outliers were detected when 
the results were screened using the single and double Grubbs test. 
In addition, the data were evaluated against storage time and regression lines of B2M mass 
concentration versus time were constructed. The slopes of the regression lines were not 
significantly different from zero (on 99 % confidence level) for all temperatures when they 
were tested for significance (loss/increase due to shipping conditions). 
The results of the measurements are shown in Annex B. 
No technically unexplained outliers/statistical outliers were detected for B2M and none of the 
trends were statistically significant at a 99 % confidence level for any of the temperatures. 
Therefore, the material was found to be stable at all temperatures for B2M. Nevertheless, for 
some other proteins certified in this material, some trends were found at 60 °C. Therefore, 
the material shall be shipped under cooled conditions. 
5.2 Long-term stability study 
For the long-term stability study, units were stored at -70 °C for 0, 2, 4, 8, 10 and 12 months 
and at -20 °C for 0, 2, 8 and 12 months. The reference temperature was set to  
-150 °C (above liquid nitrogen). two units per storage time were selected using a random 
stratified sampling scheme. Three samples were taken from each unit and were measured 
by immunonephelometry. The measurements were performed under repeatability conditions, 
in a random sequence to be able to separate any potential analytical drift from a trend over 
storage time. 
The data were evaluated for each temperature individually. No outliers were detected when 
the results were screened for outliers using the single and double Grubbs test. 
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Regression analyses were performed to evaluate potential trends in the analytical sequence 
as well as trends in the filling sequence. Some significant (at 99 % confidence level) trends in 
the analytical sequence were observed (see Annex C - Figure C-1). As the analytical 
sequence and the unit numbers were not correlated, correction for these trends can improve 
the sensitivity of the subsequent statistical analysis through a reduction in analytical variation 
without masking potential between-unit heterogeneities. Therefore, trends in the analytical 
sequence were corrected as the trend was significant on at least a 99 % confidence level as 
shown in Equation 4. 
	 = !"	 − $	 × 	 Equation 4 
$ = slope of the linear regression 
	 = position of the result in the analytical sequence 
Furthermore, the data were plotted against storage time and linear regression lines of mass 
concentration versus time were calculated. The slope of the regression lines was tested for 
statistical significance (loss/increase due to storage conditions). For B2M, the slopes of the 
regression lines were not significantly different from zero (at a 99 % confidence level) for 
both -20 °C and -70 °C.  
The results of the long term stability measurements are shown in Annex C.  
No technically unexplained outliers were observed and none of the trends was statistically 
significant at a 99 % confidence level for any of the temperatures. As for the short-term 
stability, the storage temperature was based on all the parameters certified in the material. 
The material must therefore be stored at -70 °C. 
5.3 Estimation of uncertainties 
Due to the intrinsic variation of measurement results, no study can entirely rule out 
degradation of materials, even in the absence of statistically significant trends. It is therefore 
necessary to quantify the potential degradation that could be hidden by the method 
repeatability, i.e. to estimate the uncertainty of stability. This means that even under ideal 
conditions the outcome of a stability study can only report that there was no detectable 
degradation during the time frame studied. 
Uncertainties of stability during dispatch and storage were estimated, as described in [15]. In 
this approach, the uncertainty of the linear regression line with a slope of zero was 
calculated. The uncertainty contributions usts and ults are calculated as the product of the 
chosen transport time/shelf life and the uncertainty of the regression lines as in Equation 5 
and 6: 
( ) ttirelsts ttt
RSD
u ⋅
−
=
∑
2,
 Equation 5 
( ) slirellts ttt
RSD
u ⋅
−
=
∑
2,
 Equation 6 
RSD  relative standard deviation of all results of the stability study 
it  time elapse at point i 
t  mean of all it  
ttt chosen transport time (1 week at 4 ºC) 
tsl chosen shelf life (12 months at -70 ºC) 
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The following uncertainties were estimated: 
- usts,rel, the uncertainty of degradation during dispatch. This was estimated from the 
4 °C studies. The uncertainty describes the possible change during a dispatch at 
4 °C lasting for one week. 
- ults,rel, the stability during storage. This uncertainty contribution was estimated from 
the -70 °C studies. The uncertainty contribution describes the possible degradation 
during 12 months storage at -70 °C.  
The results of these evaluations are summarised in Table 2. 
Table 2: Uncertainties of stability during dispatch and storage. usts,rel was calculated for 
a temperature of 4 °C and 1 week; ults,rel was calculated for a storage temperature of  
-70 °C and 1 year. 
 
usts ,rel 
[%] 
ults,rel 
[%] 
B2M 0.27 0.62 
 
After the certification study, the material will be included in IRMM's regular stability 
monitoring programme to determine its future stability. 
The characterisation of B2M was performed later than the other certified proteins in this CRM 
and therefore the stability of the material beyond the established 12 months shelf life was 
assessed. This was performed by comparative analysis of two units of the CRM stored at the 
normal storage temperature (-70 °C) and two units stored at the reference temperature  
(-150 °C above liquid nitrogen) directly after the material processing. Storage of the 
reference samples at -150 °C is assumed to render the material degradation negligible. All 
the samples were analysed (in triplicate for each unit) by immunonephelometry. 
The results of the normal stock samples (stored at -70 °C) were compared with the results for 
the reference stock within their respective uncertainties. The uncertainty of the dedicated 
measurements was established as the standard deviation divided by the square root of the 
number of measurements. A comparison of normalised results was performed to assess the 
consistency of the data and the assumption that the material is stable. The normalisation was 
performed as described below:  
- the normal stock results were divided by the results obtained from analysis of the 
reference samples, 
- the certified value was set to 1, 
- the expanded standard uncertainty of the dedicated measurements was established 
as in Equation 7: 
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where: 
Umeas expanded standard measurement uncertainty with coverage factor, k = 2 
sns, sref standard deviations of results of normal stock samples and reference samples, 
respectively 
nns, nref number of results of normal stock samples and reference samples, respectively 
nsx , refx  mean of all results of normal stock samples and reference samples, respectively 
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There was no difference between the results from the normal stock and the results from the 
reference stock thus confirming the stability of ERM-DA470k/IFCC with regard to B2M mass 
concentration as can be seen in Table 3. 
Table 3: Results of the stability test on ERM-DA470k/IFCC. 
 
nsx ± sns [mg/L] 
nns = 6 
refx ± sref [mg/L] 
nref = 6 
Ratio ± Umeas 
B2M 2.40 ± 0.05 2.38 ± 0.04 1.007 ± 0.021 
6 Characterisation  
The material characterisation is the process of determining the property value(s) of a 
reference material. 
This was based on an inter-laboratory comparison by expert laboratories, i.e. the mass 
concentration of beta-2-microglobulin in the material was determined in different laboratories 
which applied different measurement procedures to demonstrate the absence of a 
measurement bias. Due to the nature of the analyte however, all participants used 
immunoassays for the measurements. This approach aims to negate laboratory bias, which 
reduces the combined uncertainty. 
6.1 Selection of participants 
Thirteen laboratories were selected based on criteria that comprised both technical 
competence and quality management. Each participant laboratory was required to operate a 
quality system and to deliver documented evidence of proficiency in the field of protein 
measurements in human serum by submitting results for inter-laboratory comparison 
exercises or method validation reports. Having a formal accreditation was not mandatory, but 
meeting the requirements of ISO/IEC 17025 [4] was obligatory. Most measurements were 
performed under an ISO 13485 quality management system [16] and the certification 
numbers are stated in the list of participants (Section 2). 
6.2 General principles 
The characterisation of B2M in the human serum reference material ERM-DA470k/IFCC was 
performed according to the principles as documented in [12] and [17]. The characterisation 
was achieved by calibrating the measurements of the candidate reference material with a 
pure protein reference solution. The pure protein solution had been previously assigned a 
value for its B2M mass concentration. The practical transfer protocol is based on duplicate 
measurements of 6 dilutions of the pure protein solution and 6 dilutions of the candidate 
reference material under conditions as repeatable as possible. The transfer protocol requires 
several measurements a day (three in this study) repeated on several days (four in this 
study). An important prerequisite for this transfer study was that all reconstitutions and 
dilutions were controlled by weighing, thus reducing uncertainty in the transfer. 
The following definitions apply ([12] and [17]) to the transfer procedure: 
The reference preparation (pure protein solution) is defined as the protein preparation with 
known concentration value (Table 4) used as calibrant. The solution was prepared by 
extensive dialysis of lyophilised B2M reconstituted in 0.1 mol/L potassium chloride. The 
target concentration was approximately 1 g/L. The solution was assigned a value by amino 
acid analysis [18]. The results were confirmed by measurement of this solution by amino acid 
analysis in a second laboratory [19] and dry mass determination [20]. 
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The purity of the protein was assessed by polyacrylamide gel electrophoresis and by 
capillary electrophoresis. No additional bands or peaks were detected thus giving an 
uncertainty for purity equal to the limit of detection of the individual methods. When 
comparing these limit of detection to &'(),*+), they were considered to be negligible and were 
not included in the uncertainty budget for the pure protein solution. 
Table 4: Assigned value and expanded uncertainty of B2M in the pure protein solution 
Assigned value [mg/L] ucal,rel [%] 
917 1.05 
 
Target material (TM) is defined as the serum protein matrix material with unknown 
concentration value. In this case it is the matrix material ERM-DA470k/IFCC. 
The transfer method should be based on well-established and recognised methods used in 
clinical chemistry. In this characterisation study, immunonephelometry, immunoturbidimetry, 
fluorometric enzyme immunoassay and chemiluminescent immunoassay were used. 
Slight variations in the assay conditions, in the programming of the instruments or in the 
reagents may lead to different results. This has led to the prerequisite of method 
standardisation [21]. To minimise the factors contributing to variation, an optimised and 
practical transfer protocol was prepared with detailed instructions and emphasis on weighing 
all solutions used to prepare dilutions. Specific registration forms containing the intended 
dilution schemes were used to report the raw data. These forms were subsequently collected 
for treatment of the raw data. 
In total, sixty different sets of the B2M dilution series (five increasing concentrations ranging 
from 1 to 5 mg/L and one blank solution) were prepared from the pure protein solution. Each 
laboratory received four different sets (each set with the six concentrations) chosen 
randomly. 
Six dilutions of the target material (TM) were prepared on each day at each laboratory from a 
different ERM-DA470k/IFCC unit. The dilutions were performed by weighing to determine a 
gravimetric dilution factor. For this purpose, the dilution factors were calculated using the 
following densities: 1.0051 for saline solution, 1.0174 for saline solution containing 5 % (w/v) 
bovine serum albumin and 0.9982 for distilled water (water density at 20 °C). The 
concentration of the specific protein (although still unknown) in each dilution will be as in 
Equation 9: 
() = ,() ×  Equation 8 
where 
 is the dilution factor of TM and (	) denotes the different dilutions (	 =1-6). 
Participating laboratories were instructed to use their common in-house calibrant to 
determine the dose-response function of the instrument. 
A regression line was constructed comparing the gravimetrically calculated concentrations 
(as determined gravimetrically) in the dilutions of the pure protein solution to the measured 
concentrations. 
The slope and intercept were determined for each of the runs and used to interpolate the 
measured value of the dilutions of the target material. 
The initial concentration in the target material is then calculated using the dilution factor 
. 
Dilutions 1 and 2 for the target material were outside the range of the regression line 
obtained with the pure protein solution dilutions and were therefore not used for calculations. 
The eight remaining values (four dilution points measured in duplicate) were then used to 
determine the concentration in the target material in each run. 
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On each of the four days, a new set of vials of the reference preparation (blank and five 
different concentrations) and one new unit of the target material were used and a new set of 
dilutions prepared. Each day three calibrations were performed together with determinations 
of samples and controls (i.e., 3 runs). 
The methods including instruments, dilution buffers, antibodies and reagents and 
laboratories are listed in Annex D. 
6.3 Calculation of the dilutions 
The liquids used for the reconstitution of the materials and for the preparation of the dilutions 
were weighed to a standard deviation of maximum 0.0001 g (with the exception of one 
laboratory). 
The density of the solutions were either provided by the participating laboratories or 
measured, at IRMM, on a DMA 4500 M densitometer (Anton Paar, Graz, AT). 
The following mass corrections were applied: 
For the reconstitution of ERM-DA470k/IFCC with ultrapure water, as in Equation 10: 
, =
-./+.0+0
-,
 Equation 9 
where !1233 is the mass intended to be added (1.0000 g), and !,1 is the measured 
mass of water added to the vial. 
For the dilutions as in Equation 11: 
4,5 =
-4,
64,
-4,
74,
8
-44,
744,
 Equation 10 
For the dilution 9 of the material 	 with !:,1 and ρ:,1 corresponding respectively to the 
mass and to the density of the reconstituted material, and !::,1 and <::,1 corresponding 
respectively to the mass and to the density of the diluent for dilution 9. 
The concentration 1= (with c = m/V (mass / volume) and the unit (mg/L)) of B2M in the 
dilutions is calculated via Equation 12: 
'5 = '> × , × ?, × 4,5 Equation 11 
With @1 being the concentration of B2M in material 	 and 1= the concentration of B2M in 
dilution 9 of the material 	. 
6.4 Evaluation of results 
The characterisation study resulted in thirteen datasets. All individual results of the 
participants are shown in tabular form in Annex E.  
6.4.1 Technical evaluation 
The data were first evaluated for compliance with the analysis protocol provided to each 
participating laboratory and for their technical validity. The following criteria were considered 
during the evaluation:  
The following analyses were performed on all data: 
• test for normality (visual inspection and normal probability plot) 
• test for linearity (visual inspection and evaluation of r2) 
The following general acceptance criteria were applied to the datasets: 
• r2 of the regression must be above 0.98 for all measurement systems 
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• data from at least four dilutions must be available 
• The dataset from any one day must contain at least 50 % of the data generated on 
that day, otherwise all the data generated on that day are declared non-valid 
• At least two daily value assignments must be valid 
• The day-to-day variation (RSD) of valid datasets for a particular laboratory must be 
equal to or below 5 % 
Rationale for the acceptance criteria (see also reference [12]): 
• Overall r2 < 0.98 of regression indicates quality problems in the measurements 
(scattering, outliers, run-to-run variation). 
Laboratory 2 found one vial from the set of dilutions of the reference solution to be broken 
upon arrival and was therefore not analysed for day 1. The analytical runs on that day were 
therefore performed with one blank and four concentrations which still covered the range 
between 1 and 5 mg/L. 
Despite these considerations, all the data sets were retained. The characterisation study 
resulted in thirteen datasets covering fifty-two days and hundred and fifty-six runs. 
6.4.2 Statistical evaluation 
The datasets accepted in section 6.4.1 were evaluated for normality of dataset means using 
kurtosis/skewness tests and normal probability plots. They were assessed for outlying means 
using the Grubbs test and using the Cochran test for outlying standard deviations, (both at a 
the 99 % confidence level). Standard deviations within (swithin) and between (sbetween) 
laboratories were calculated using one-way ANOVA. The results of these evaluations are 
shown in Table 5. 
Table 5: Statistical evaluation of the technically accepted datasets for B2M. p: number 
of technically valid datasets 
 p Outliers Normally 
distributed 
Statistical parameters  
Means Variances Mean 
[mg/L] 
s 
[mg/L] 
sbetween 
[mg/L] 
swithin 
[mg/L] 
B2M 13 1 0 Yes 2.17 0.04 0.04 0.10 
The laboratory means followed normal distributions and none of the data contains outlying 
variances. Laboratory L5 was flagged as an outlier for the mean by the Nalimov test. This 
result was compared to the rest of the data using the principles described in the Application 
Note 1 [22]. For this, the uncertainties were estimated respectively as the relative standard 
deviation of the laboratory L5 and the relative standard deviation of the combined results 
from the thirteen other laboratories. The conclusion was that there was no significant 
difference between the individual result and the rest of the datasets. The datasets were 
therefore consistent and the mean of laboratory means was a good estimate of the true 
value.  
The results of the characterisation campaign are presented in Figure 1. 
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Figure 1: Results of the characterisation measurements for B2M. The bars represent the 
laboratory means ± 2s. The full line represents the mean of the means and the dotted lines 
represent the mean of means ± 2s. 
Laboratory code
0 1 2 3 4 5 6 7 8 9 10 11 12 13
be
ta
-
2-
m
ic
ro
gl
o
bu
lin
 
in
 
m
g/
L
2.0
2.1
2.2
2.3
2.4
 
 
The uncertainty for the characterisation exercise was estimated as the relative standard 
uncertainty of the mean of laboratory means, i.e., with s the relative standard deviation of the 
mean of laboratory means and p the number of datasets, converted into a relative value: 
uchar, rel = 0.45 %. 
7 Value Assignment 
During this study, a certified value was assigned. 
Certified values are values that fulfil the highest standards of accuracy. Full uncertainty 
budgets in accordance with the 'Guide to the Expression of Uncertainty in Measurement' [5] 
were established.  
7.1 Certified values and their uncertainties 
The unweighted mean of the means of the accepted datasets as shown in Table 5 was 
assigned as certified value for B2M.  
The assigned uncertainty consists of uncertainties relating to characterisation, uchar, rel and to 
the calibrant used ucal, rel (Section 6), potential between-unit inhomogeneity, ubb, rel (Section 
4.1) and potential degradation during transport (usts, rel) and long-term storage, ults, rel (Section 
5). These different contributions were combined to estimate the expanded, relative 
uncertainty of the certified value (UCRM, rel) with a coverage factor k as:  
2
rel lts,
2
rel sts,
2
rel bb,
2
rel cal,
2
rel char,rel CRM, uuuuukU ++++⋅=  Equation 12 
- uchar,rel was estimated as described in Section 6  
 19 
- ucal, rel is the relative standard uncertainty from the pure protein solution as described 
in section 6 
- ubb, rel was estimated as described in Section 4.1. 
- usts, rel was estimated as described in section 5.3 
- ults, rel was estimated as described in Section 5.3.  
Because of the sufficient numbers of the degrees of freedom of the different uncertainty 
contributions, a coverage factor k of 2 was applied, to obtain the expanded uncertainties. The 
certified values and their uncertainties are summarised in Table 6. 
 
Table 6: Certified values and their uncertainties for B2M in ERM-DA470k/IFCC 
 
Certified 
value 
[mg/L] 
uchar, rel 
[%] 
ucal, rel 
[%] 
ubb, rel 
[%] 
usts, rel 
[%] 
ults, rel 
[%] 
UCRM, rel 
[%] 
UCRM 
[mg/L] 2) 
B2M1) 2.17 0.45 1.05 0.67 0.27 0.62 2.95 0.07 
1) When reconstituted according to the specified procedure (see section 9.3) 
2)
 Expanded (k = 2) and rounded uncertainty. 
8 Metrological traceability and commutability 
8.1 Metrological traceability 
Identity 
Beta-2-microglobulin protein in the pure protein solution used for calibration is a clearly 
defined analyte whose identity was confirmed by Size Exclusion Chromatography, semi-
native gel electrophoresis, 2-D gel electrophoresis and immunoassay response. The 
measurand in the pure protein solution is therefore structurally defined and independent of 
the measurement method. 
The participating laboratories used different methods for the final determination, different 
dilution buffers, antibodies and reagents, demonstrating absence of measurement bias. 
However, the characterisation of the matrix material ERM-DA470k/IFCC was performed 
using only immunoassay-based methods and therefore the measurand is defined as beta-2-
microglobulin as measured by the immunoassays used in the presented procedures. 
Quantity value 
Only validated methods were used for the determination of the assigned value. The value 
assigned to the pure protein solution is traceable to the SI. All relevant input parameters 
were calibrated with this material. The individual results are therefore traceable to the SI, as 
was confirmed by the agreement among the technically accepted datasets. As the assigned 
values are combinations of consensus results individually traceable to the SI, the assigned 
quantity values themselves are also traceable to the SI. 
8.2 Commutability 
Many measurement procedures include one or more steps, which are selecting specific (or 
specific groups) of analytes from the sample for the subsequent steps of the whole 
measurement process. Often the complete identity of these 'intermediate analytes' is not fully 
known or taken into account. Therefore, it is difficult to mimic all the analytically relevant 
properties of real samples within a CRM. The degree of equivalence in the analytical 
behaviour of real samples and a CRM with respect to various measurement procedures 
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(methods) is summarised in a concept called 'commutability of a reference material'. There 
are various definitions that define this concept. For instance, the CSLI Guideline C-53A [23] 
recommends the use of the following definition for the term commutability: 
"The equivalence of the mathematical relationships among the results of different 
measurement procedures for an RM and for representative samples of the type intended 
to be measured." 
The commutability of a CRM defines its fitness for use and is therefore a crucial 
characteristic when applying different measurement methods. When the commutability of a 
CRM is not established in such cases, the results from routinely used methods cannot be 
legitimately compared with the certified value to determine whether a bias exists in 
calibration, nor can the CRM be used as a calibrant. For instance, CRMs intended to be used 
to establish or verify metrological traceability of routine clinical measurement procedures 
must be commutable for the routine clinical measurement procedures for which they are 
intended to be used. 
For beta-2-microglobulin, ERM-DA470k/IFCC and its dilutions prepared using the assay 
diluent were shown to be commutable for combinations of the following platforms: Beckman 
Coulter Immage with Beckman Coulter reagents; Beckman Coulter AU640 with Beckman 
Coulter reagents and Siemens BN ProSpec with Siemens reagents. The dilutions of the pure 
protein solution were proven to be commutabIe with the following platforms: Beckman 
Coulter AU480 with Beckman Coulter reagents, Hitachi 917 with DAKO reagents and 
Siemens BN ProSpec with Siemens reagents. If ERM-DA470k/IFCC is used for the 
calibration of other beta-2-microglobulin assays other than the ones used during the 
certification study it should be verified by the user that the material or its dilution used is 
commutable for that particular method in combination with other methods. 
9 Instructions for use 
9.1 Safety information 
The usual laboratory safety measures apply. 
Avoid swallowing as well as contact with skin. Do not discharge the waste into the drain. 
Each portion of donated blood used in the production of the material has been tested for the 
presence of HBs antigen, HCV, HIV1/HIV2, and HTLV1 antibodies and found to be negative. 
However, the product must be handled with adequate care as any material of human origin. 
It is intended for in vitro analysis only.  
9.2 Storage conditions 
Unopened vials should be stored at - (70 ± 5) °C. Under the condition that any microbial 
contamination during the reconstitution procedure has been excluded, the solution of ERM-
DA470k/IFCC can be used for one week. It is advisable to cover the vial with the original seal 
after use and to store it at 2 to 8 °C.  
Please note that the European Commission cannot be held responsible for changes that 
happen during storage of the material at the customer's premises, especially of opened vials. 
9.3 Intended use and instructions for use 
The material is primarily intended to be used for the calibration of immunoassay-based in 
vitro diagnostic devices or control products for the proteins certified. As for any calibrator it 
should be verified that it is commutable. The material was produced in a similar manner as 
ERM-DA470, the use of which has led to a significant reduction in the between-method and 
between-laboratory variation for the proteins certified [8, 9]. It was verified during the value 
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assignment procedure that there were no significant matrix effects, and that different 
methods produced consistent results. However, when the material is used as a calibrator, the 
commutability should be verified for the particular assay concerned. 
The entire content of the vial must be reconstituted. 
Reconstitution of the material 
To make it ready for use, the material has to be reconstituted according to the following 
procedure: 
• Remove the vial from the freezer during the afternoon of the day before use and 
place the vial for 1 hour in the room where the balance is located. 
• After 1 hour tap the bottom of the vial gently on the surface of the table. Make sure 
that all the material has settled down on the bottom of the vial. Remove the screw 
cap. 
• Weigh the vial together with the rubber stopper. Note the mass or press the “TARE” 
button on the balance. Lift the rubber stopper with care until air is allowed to enter the 
vial and the groove in the rubber stopper becomes accessible. 
• Add 1.00 mL of ultrapure water through the groove, and press the rubber stopper 
back into place. Weigh the vial and note the mass. If you have used the “TARE” 
function, the value can be used directly for the mass m. Otherwise the first mass must 
be subtracted from the second to obtain m. 
• The concentration of B2M in the solution, corrected for the reconstitution mass, can 
be obtained by multiplying the certified value for that protein with mintended / m, with 
mintended the mass intended to be added (1.000 g). 
• Leave the vial at room temperature for one hour, then invert it carefully at least five 
times (do not shake it) during the next hour. 
• Leave the vial at room temperature overnight. On the day of use invert the vial 
carefully five times during one hour. 
9.4 Minimum sample intake 
The minimum volume of reconstituted sample to be used is 2 µL. 
9.5 Use of the certified value 
The material is primarily intended to be used to calibrate serum-based protein standards and 
control materials of organisations that offer such preparations for the quantification of B2M by 
immunoassay. 
 
Use as a calibrant 
The uncertainty of the certified value shall be taken into account in the estimation of the 
measurement uncertainty. 
Comparing an analytical result with the certified value 
A result is unbiased if the combined standard uncertainty of measurement and certified value 
covers the difference between the certified value and the measurement result (see also ERM 
Application Note 1, www.erm-crm.org [22]. 
For assessing the method performance, the measured values of the CRMs are compared 
with the certified values. The procedure is described here in brief:  
- Calculate the absolute difference between mean measured value and the certified 
value (∆meas). 
- Combine measurement uncertainty (umeas) with the uncertainty of the  
certified value (uCRM): 22 CRMmeas uuu +=∆  
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- Calculate the expanded uncertainty (U∆) from the combined uncertainty (u∆,) using an 
appropriate coverage factor, corresponding to a level of confidence of approximately 
95 %. 
- If ∆meas ≤ U∆ no significant difference between the measurement result and the 
certified value, at a confidence level of about 95 % exists. 
Use in quality control charts 
The materials can be used for quality control charts. Different CRM-units will give the same 
result as inhomogeneity was included in the uncertainties of the certified values.  
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Annexes 
Annex A: Results of the homogeneity measurements 
Figure A-1: Concentration of B2M in 40 units of ERM-DA470k/IFCC determined during the 
homogeneity study (standard deviation for the three replicates shown). 
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Annex B: Results of the short-term stability measurements 
Figure B-1: Concentration of B2M in ERM-DA470k/IFCC stored at 60 °C during the short-
term stability study 
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Figure B-2: Concentration of B2M in ERM-DA470k/IFCC stored at 4 °C during the short-term 
stability study 
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Figure B-3: Concentration of B2M in ERM-DA470k/IFCC stored at -20 °C during the short-
term stability study 
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Figure B-4: Concentration of B2M in ERM-DA470k/IFCC stored at -70 °C during the short-
term stability study 
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Annex C: Results of the long-term stability measurements 
Figure C-1: Regression analysis of the results in the analytical sequence order (before trend 
correction) 
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Figure C-2: Concentration of B2M in ERM-DA470k/IFCC stored at -20 °C during the long-
term stability study 
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Figure C-3: Concentration of B2M in ERM-DA470k/IFCC stored at -70 °C during the long-
term stability study 
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Annex D: Summary of methods used in the characterisation study 
Laboratory Method Instrument Dilution Buffer Antibody Reagent 
L1 Immunoturbidimetry Abbott 
Architect® 
c8000 
Saline solution Abbott 
polystyrene 
latex particles 
coated IgG 
anti-human 
B2M (rabbit) 
Phosphate 
Buffer + 
Bovine Serum 
Albumin 
L2 Fluorometric enzyme 
immunoassay 
TOSOH AIA-
2000 
TOSOH AIA-Pack BMG Kit containing all the 
reagents 
L3 Immunoturbidimetry Roche 
Cobas c501 
Saline Roche latex 
particles coated 
with polyclonal 
α-human-β-2-
microglobulin 
antibody 
TRIS/HCl 
Buffer with 
NaCl and 
EDTA 
L4 Immunoturbidimetry Hitachi 917 Saline BMG-Latex X1 "SEIKEN" Kit 
containing antibody and 
reagent 
L5 Immunoturbidimetry Hitachi 7180 Saline with 
5 % BSA 
A&T 
Immunoticles 
Auto β2-m  
R-2 
A& T 
Immunoticles 
Auto β2-m  
R-1 
L6 Immunoturbidimetry Hitachi 7180 Saline LZ TEST 
'EIKEN' β2m 
LZ TEST 
'EIKEN' β2m 
L7 Immunonephelometr
y 
Siemens BN 
ProSpec 
Siemens  
N-Diluent 
Siemens  
N Latex β2- 
microglobulin 
Siemens  
N Reaction 
Buffer 
L8 Chemiluminescent 
immunoassay 
SpherelightT
M
 Wako 
Wako 
SpherelightTM 
Dilution Buffer 
Wako SpherelightTM β2-m Kit 
L9 Immunoturbidimetry Hitachi 7180 Nittobo BMG 
dilution buffer 
Nittobo N-Assay LA  
β2-MG-HII 
L10 Immunoturbidimetry Beckman 
Coulter 
AU480 
Distilled water Beckman 
Coulter latex 
particles coated 
with rabbit IgG 
anti-human  
β-2-
microglobulin 
Beckman 
Coulter  β-2-
microglobulin 
reagent 
L11 Immunoturbidimetry Hitachi 7180 Saline Superior BMG-II (DKL/LSI 
Medience) 
L12 Immunoturbidimetry Hitachi 7180 Saline Wako β2m-
Latex Reagent 
Wako β2m-LT 
Buffer 
L13 Immunoturbidimetry Hitachi 917 MilliQ water Dako B2M 1a Dako B2M 
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Annex E: Results of the characterisation measurements in mg/L 
 
Laboratory Day Run 1 Run 2 Run 3 
L1 
1 2.16 2.28 2.26 
2 2.17 2.20 2.22 
3 2.20 2.20 2.23 
4 2.10 2.11 2.18 
L2 
1 2.11 2.16 2.17 
2 2.28 2.22 2.23 
3 2.26 2.23 2.26 
4 2.24 2.24 2.27 
L3 
1 2.16 2.23 2.22 
2 2.17 2.12 2.15 
3 2.23 2.25 2.28 
4 2.14 2.14 2.16 
L4 
1 2.19 2.18 2.15 
2 2.19 2.17 2.17 
3 2.15 2.17 2.17 
4 2.05 2.06 2.05 
L5 
1 2.06 2.04 2.06 
2 2.13 2.14 2.13 
3 2.08 2.07 2.05 
4 2.13 2.13 2.12 
L6 
1 2.18 2.19 2.20 
2 2.24 2.23 2.21 
3 2.10 2.10 2.19 
4 2.08 2.06 2.07 
L7 
1 2.02 2.15 2.11 
2 2.18 2.25 2.25 
3 2.11 2.17 2.14 
4 2.21 2.28 2.24 
L8 
1 2.25 2.25 2.22 
2 2.21 2.22 2.18 
3 2.22 2.25 2.22 
4 2.24 2.19 2.20 
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L9 
1 2.14 2.17 2.12 
2 2.24 2.26 2.20 
3 2.16 2.17 2.16 
4 2.19 2.19 2.20 
L10 
1 2.15 2.05 2.09 
2 2.22 2.19 2.23 
3 2.17 2.15 1.98 
4 2.17 2.13 2.18 
L11 
1 2.17 2.16 2.22 
2 2.18 2.13 2.08 
3 2.15 2.06 2.15 
4 2.26 2.19 2.20 
L12 
1 2.20 2.19 2.19 
2 2.24 2.24 2.24 
3 2.15 2.16 2.15 
4 2.10 2.09 2.09 
L13 
1 2.24 2.23 2.24 
2 2.19 2.18 2.16 
3 2.29 2.26 2.24 
4 2.08 2.10 2.10 
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